MT 7716

Drug Profile

MT 7716

Alternative Names: MT-7716

Latest Information Update: 10 May 2013

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism

Most Recent Events

  • 08 May 2013 Discontinued - Phase-I for Alcoholism in USA (unspecified route)
  • 31 Oct 2011 Phase-I clinical trials in Alcoholism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top